tradingkey.logo

Glucose monitor maker Dexcom's prelim Q4 revenue beats expectations on G7 15 Day launch

ReutersJan 12, 2026 12:41 PM


Overview

  • Glucose biosensing firm's preliminary Q4 revenue rises 13%, beating analyst expectations

  • Fiscal 2025 revenue grows 16% yr/yr, driven by sensor technology launch

  • Company anticipates 11-13% revenue growth in 2026, driven by sensor volume growth


Outlook

  • Dexcom anticipates 2026 revenue of $5.16 - $5.25 bln, growth of 11-13% over 2025

  • Company expects 2026 non-GAAP gross profit margin of 63-64%

  • Dexcom forecasts 2026 non-GAAP operating margin of 22-23%


Result Drivers

  • G7 SENSOR LAUNCH - Dexcom's Q4 revenue growth driven by the launch of G7 15 Day sensor technology, per CEO Jake Leach

  • INTERNATIONAL EXPANSION - International revenue increased by 18% in Q4, reflecting strong global demand


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$1.26 bln

$1.24 bln (25 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 27 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Dexcom Inc is $84.71, about 25.7% above its January 9 closing price of $67.40

  • The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 28 three months ago

Press Release: ID:nBw9Sg5fsa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI